Comparison · NCT01170117-sae
Olanzapine vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Olanzapine vs Placebo: serious adverse events. Trial comparisons, record NCT01170117-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01170117-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.213 | 0.136 | 0.319 | wilson | |
| Risk in group 2 | 0.169 | 0.101 | 0.268 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0445 | -0.0812 | 0.17 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.26 | 0.654 | 2.44 | log | |
| Odds ratio, group 1 over group 2 | 1.34 | 0.592 | 3.01 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Olanzapine than on Placebo | 22.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Olanzapine | Group receiving olanzapine~Olanzapine: Dosing of olanzapine will begin at 2.5 mg and will be titrated to a maximum dose of 10 mg. The target dose of 10 mg of olanzapine was selected because published data from studies that used this dose indicated that it was helpful to patients. | 16 | 75 | EG001 |
| Group 2 | Placebo | Control group receiving placebo~Placebo: Control Group will receive placebo pill. | 13 | 77 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Adverse events were collected during the 24 weeks of study participation (16 weeks of active participation, and 8 weeks of followup).
Source ClinicalTrials.gov
Trial
- Title
- Olanzapine Versus Placebo for Outpatients With Anorexia Nervosa
- NCT number
- NCT01170117
- Phases
- NA
- Conditions
- Anorexia Nervosa
- Interventions
- Olanzapine, Placebo
- Lead sponsor
- New York State Psychiatric Institute
- Results first posted
- 2017-08-25
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01170117?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01170117-sae